In vitro studies have demonstrated its anti-tumorigenic effects through transforming growth factor-β signaling [180] and decreased cell adhesion with recombinant decorin supplementation in specific breast cancer cell lines (BT474, T47D, SKBR3, HCT8/E11, SW480, and CaCo-2) [181]. This evidence concerns the gene DCN and breast cancer.